Novel therapies for inflammatory bowel disease (Q33662018)

28 July 2017

1 reference

title

Novel therapies for inflammatory bowel disease (English)

1 reference

inflammatory bowel diseases

28 July 2017

main subject

0 references

author name string

Sands BE

series ordinal

1

1 reference

28 July 2017

publication date

1 June 1999

1 reference

Gastroenterology Clinics of North America

28 July 2017

published in

1 reference

28 July 2017

volume

28

1 reference

28 July 2017

issue

2

1 reference

28 July 2017

page(s)

323-351

1 reference

A pilot study of centrifugal leukocyte apheresis for corticosteroid-resistant active ulcerative colitis

28 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2805%2970059-5

7 January 2021

Expression of transforming growth factors alpha and beta in colonic mucosa in inflammatory bowel disease

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2805%2970059-5

7 January 2021

Treatment with tumour necrosis factor inhibitor oxpentifylline does not improve corticosteroid dependent chronic active Crohn's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2805%2970059-5

7 January 2021

The tumor necrosis factor ligand and receptor families.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2805%2970059-5

7 January 2021

Effect of an enteric-coated fish-oil preparation on relapses in Crohn's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2805%2970059-5

7 January 2021

Tacrolimus (FK-506) treatment of fulminant colitis in a child

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2805%2970059-5

7 January 2021

Healing of severe perineal and cutaneous Crohn's disease with hyperbaric oxygen

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2805%2970059-5

7 January 2021

Tumour necrosis factor alpha in stool as a marker of intestinal inflammation

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2805%2970059-5

7 January 2021

Rectal irrigation with short-chain fatty acids for distal ulcerative colitis. Preliminary report

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2805%2970059-5

7 January 2021

Interleukin‐10 differentially regulates B7‐1 (CD80) and B7‐2 (CD86) expression on human peripheral blood dendritic cells

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2805%2970059-5

7 January 2021

Peripheral monocyte and naive T-cell recruitment and activation in Crohn's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2805%2970059-5

7 January 2021

The efficacy of tobramycin in the treatment of ulcerative colitis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2805%2970059-5

7 January 2021

An enteral formula containing fish oil, indigestible oligosaccharides, gum arabic and antioxidants affects plasma and colonic phospholipid fatty acid and prostaglandin profiles in pigs

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2805%2970059-5

7 January 2021

Treatment of severe Crohn's disease with anti-CD4 monoclonal antibody.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2805%2970059-5

7 January 2021

The Th1/Th2 balance in autoimmunity

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2805%2970059-5

7 January 2021

Interleukin-6 family of cytokines induced activation of different functional sites expressed by gp130 transducing protein

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2805%2970059-5

7 January 2021

Growth factor mRNA expression in normal colorectal mucosa and in uninvolved mucosa from ulcerative colitis patients

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2805%2970059-5

7 January 2021

Humanized antibodies for therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2805%2970059-5

7 January 2021

Hyperbaric oxygenation in severe perineal Crohn's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2805%2970059-5

7 January 2021

A dose‐ranging pharmacokinetic study of nicotine tartrate following single‐dose delayed‐release oral and intravenous administration

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2805%2970059-5

7 January 2021

CD4+ T Cells Reactive to Enteric Bacterial Antigens in Spontaneously Colitic C3H/HeJBir Mice: Increased T Helper Cell Type 1 Response and Ability to Transfer Disease

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2805%2970059-5

7 January 2021

Role of reactive metabolites of oxygen and nitrogen in inflammatory bowel disease: toxins, mediators, and modulators of gene expression

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2805%2970059-5

7 January 2021

Chronic exposure to tumor necrosis factor (TNF) in vitro impairs the activation of T cells through the T cell receptor/CD3 complex; reversal in vivo by anti-TNF antibodies in patients with rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2805%2970059-5

7 January 2021

Tolerability of interferon alpha-2b, a possible new treatment of active Crohn's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2805%2970059-5

7 January 2021

In vivo butyrate metabolism and colonic permeability in extensive ulcerative colitis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2805%2970059-5

7 January 2021

Interleukin 10(IL-10) inhibits cytokine synthesis by human monocytes: an autoregulatory role of IL-10 produced by monocytes

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2805%2970059-5

7 January 2021

Trefoil peptides promote epithelial migration through a transforming growth factor beta-independent pathway

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2805%2970059-5

7 January 2021

Tolerance towards resident intestinal flora in mice is abrogated in experimental colitis and restored by treatment with interleukin-10 or antibodies to interleukin-12

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2805%2970059-5

7 January 2021

'Sticky' neutrophils, pathergic arthritis, and response to heparin in pyoderma gangrenosum complicating ulcerative colitis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2805%2970059-5

7 January 2021

Reduced susceptibility of mice overexpressing transforming growth factor alpha to dextran sodium sulphate induced colitis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2805%2970059-5

7 January 2021

Taming TNF: strategies to restrain this proinflammatory cytokine

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2805%2970059-5

7 January 2021

Octreotide effectively decreases mucosal damage in experimental colitis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2805%2970059-5

7 January 2021

Inflammatory bowel disease: the asthma of the intestine?

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2805%2970059-5

7 January 2021

Phase II trial of copper zinc superoxide dismutase (CuZnSOD) in treatment of Crohn's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2805%2970059-5

7 January 2021

Treatment of inflammatory bowel disease with anti-CD4 monoclonal antibody

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2805%2970059-5

7 January 2021

Treatment of ulcerative colitis with an engineered human anti-TNFalpha antibody CDP571.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2805%2970059-5

7 January 2021

Treatment of corticosteroid-resistant ulcerative colitis with heparin--a report of 16 cases.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2805%2970059-5

7 January 2021

Inflammatory bowel disease: etiology and pathogenesis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2805%2970059-5

7 January 2021

Effect of ciprofloxacin on the accumulation of interleukin-6, interleukin-8, and nitrite from a human endothelial cell model of sepsis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2805%2970059-5

7 January 2021

Prospective evaluation of interferon-alpha in treatment of chronic active Crohn's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2805%2970059-5

7 January 2021

Processing of tumour necrosis factor-α precursor by metalloproteinases

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2805%2970059-5

7 January 2021

Immunosuppressive agents: recent developments in molecular action and clinical application

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2805%2970059-5

7 January 2021

Pharmacokinetics of nicotine carbomer enemas: a new treatment modality for ulcerative colitis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2805%2970059-5

7 January 2021

Nicotine enemas for active ulcerative colitis—a pilot study

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2805%2970059-5

7 January 2021

Combination Ciprofloxacin and Metronidazole for Active Crohn’s Disease

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2805%2970059-5

7 January 2021

Two-year-outcomes analysis of Crohn's disease treated with rifabutin and macrolide antibiotics

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2805%2970059-5

7 January 2021

Treatment of diversion colitis with short-chain-fatty acid irrigation

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2805%2970059-5

7 January 2021

Delayed effect of desmopressin on circulating neutrophils and monocytes

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2805%2970059-5

7 January 2021

A trial of zileuton versus mesalazine or placebo in the maintenance of remission of ulcerative colitis. The European Zileuton Study Group For Ulcerative Colitis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2805%2970059-5

7 January 2021

Treatment of ulcerative colitis with fish oil supplementation: a prospective 12 month randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2805%2970059-5

7 January 2021

Ketotifen therapy for acute ulcerative colitis in children: a pilot study

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2805%2970059-5

7 January 2021

Epithelial cells as sensors for microbial infection

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2805%2970059-5

7 January 2021

Substance-P-mediated intestinal inflammation: inhibitory effects of CP 96,345 and SMS 201-995

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2805%2970059-5

7 January 2021

Somatostatin in the idiopathic inflammatory bowel diseases

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2805%2970059-5

7 January 2021

IBD: A Vascular Disorder? The Case for Heparin Therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2805%2970059-5

7 January 2021

Double-blind comparison of an oral Escherichia coli preparation and mesalazine in maintaining remission of ulcerative colitis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2805%2970059-5

7 January 2021

Interleukin-10-deficient mice develop chronic enterocolitis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2805%2970059-5

7 January 2021

Antiviral effect of TNF-alpha and IFN-gamma secreted from a CD8+ influenza virus-specific CTL clone

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2805%2970059-5

7 January 2021

In vivo profiles of eicosanoids in ulcerative colitis, Crohn's colitis, and Clostridium difficile colitis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2805%2970059-5

7 January 2021

Does vitamin E supplementation modulate in vivo arachidonate metabolism in human inflammation?

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2805%2970059-5

7 January 2021

Hyperbaric oxygen for perianal Crohn's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2805%2970059-5

7 January 2021

Oral tobramycin in ulcerative colitis: effect on maintenance of remission.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2805%2970059-5

7 January 2021

Supplementation with n-3 fatty acids from fish oil in chronic inflammatory bowel disease--a randomized, placebo-controlled, double-blind cross-over trial

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2805%2970059-5

7 January 2021

Insulin-like growth factors and inflammatory bowel disease

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2805%2970059-5

7 January 2021

Proteolytic enzymes in inflammatory bowel disease

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2805%2970059-5

7 January 2021

Tumor necrosis factor alpha (TNF-alpha)-induced cell adhesion to human endothelial cells is under dominant control of one TNF receptor type, TNF-R55.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2805%2970059-5

7 January 2021

Nicotine inhibits the in vitro production of interleukin 2 and tumour necrosis factor-alpha by human mononuclear cells

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2805%2970059-5

7 January 2021

Crohn's disease and Escherichia coli. A new approach in therapy to maintain remission of colonic Crohn's disease?

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2805%2970059-5

7 January 2021

Substance P binding sites on intestinal lymphoid aggregates and blood vessels in inflammatory bowel disease correspond to authentic NK-1 receptors

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2805%2970059-5

7 January 2021

Ketotifen treatment of active colitis in patients with 5-aminosalicylate intolerance

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2805%2970059-5

7 January 2021

Effects of ropivacaine on eicosanoid release from human granulocytes and endothelial cells in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2805%2970059-5

7 January 2021

Altered expression of alpha 4 beta 7, a gut homing integrin, by circulating and mucosal T cells in colonic mucosal inflammation

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2805%2970059-5

7 January 2021

TH1 and TH2 cells: different patterns of lymphokine secretion lead to different functional properties

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2805%2970059-5

7 January 2021

Radiologic and clinical assessment of broad-spectrum antibiotic therapy in Crohn's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2805%2970059-5

7 January 2021

Closure of refractory perineal Crohn's lesion. Integration of hyperbaric oxygen into case management

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2805%2970059-5

7 January 2021

Local administration of antisense phosphorothioate oligonucleotides to the p65 subunit of NF-kappa B abrogates established experimental colitis in mice

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2805%2970059-5

7 January 2021

Cytokines in stools of children with inflammatory bowel disease or infective diarrhoea

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2805%2970059-5

7 January 2021

Increased mucosal concentrations of soluble intercellular adhesion molecule-1 (sICAM-1), sE-selectin, and interleukin-8 in active ulcerative colitis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2805%2970059-5

7 January 2021

Circulating soluble adhesion molecules in inflammatory bowel disease

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2805%2970059-5

7 January 2021

Is there a role for antibiotics as primary therapy in Crohn's ileitis?

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2805%2970059-5

7 January 2021

Tumor necrosis factor microsatellites define a Crohn's disease-associated haplotype on chromosome 6.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2805%2970059-5

7 January 2021

Attenuation of colitis in the cotton-top tamarin by anti-alpha 4 integrin monoclonal antibody

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2805%2970059-5

7 January 2021

CP-96,345, a substance P antagonist, inhibits rat intestinal responses to Clostridium difficile toxin A but not cholera toxin

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2805%2970059-5

7 January 2021

Metronidazole plus ciprofloxacin in the treatment of active, refractory Crohn's disease: results of an open study

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2805%2970059-5

7 January 2021

Ciprofloxacin as a treatment for ulcerative colitis-not yet

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2805%2970059-5

7 January 2021

Comparison of bismuth citrate and 5-aminosalicylic acid enemas in distal ulcerative colitis: a controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2805%2970059-5

7 January 2021

Transdermal nicotine for active ulcerative colitis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2805%2970059-5

7 January 2021

Hyperbaric oxygen: a novel modality to ameliorate experimental colitis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2805%2970059-5

7 January 2021

Normal luminal bacteria, especially Bacteroides species, mediate chronic colitis, gastritis, and arthritis in HLA-B27/human beta2 microglobulin transgenic rats

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2805%2970059-5

7 January 2021

Enhanced secretion of tumour necrosis factor-alpha, IL-6, and IL-1 beta by isolated lamina propria mononuclear cells from patients with ulcerative colitis and Crohn's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2805%2970059-5

7 January 2021

Neuropeptides in inflammatory bowel disease: an update

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2805%2970059-5

7 January 2021

Protective function of extrinsic sensory neurons in acute rabbit experimental colitis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2805%2970059-5

7 January 2021

Intestinal vessels express a high density of somatostatin receptors in human inflammatory bowel disease

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2805%2970059-5

7 January 2021

Leukotrienes in ulcerative colitis: results of a multicenter trial of a leukotriene biosynthesis inhibitor, MK-591.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2805%2970059-5

7 January 2021

Role of anaerobic bacteria in the metabolic welfare of the colonic mucosa in man

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2805%2970059-5

7 January 2021

Increased expression of CD44v6 and CD44v3 in ulcerative colitis but not colonic Crohn's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2805%2970059-5

7 January 2021

Involvement of leukotrienes, TNF-alpha, and the LFA-1/ICAM-1 interaction in substance P-induced granulocyte infiltration

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2805%2970059-5

7 January 2021

Endothelial ligands and homing of mucosal leukocytes in extraintestinal manifestations of IBD.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2805%2970059-5

7 January 2021

Treatment of ulcerative colitis with fish oil n--3-omega-fatty acid: an open trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2805%2970059-5

7 January 2021

Nicotine tartrate liquid enemas for mildly to moderately active left‐sided ulcerative colitis unresponsive to first‐line therapy: a pilot study

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2805%2970059-5

7 January 2021

Transdermal nicotine for mildly to moderately active ulcerative colitis. A randomized, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2805%2970059-5

7 January 2021

Biologic therapy for inflammatory bowel disease

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2805%2970059-5

7 January 2021

Chimeric anti-TNF-α monoclonal antibody cA2 binds recombinant transmembrane TNF-α and activates immune effector functions

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2805%2970059-5

7 January 2021

Effect of butyrate enemas on the colonic mucosa in distal ulcerative colitis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2805%2970059-5

7 January 2021

T helper type 1 development of naive CD4+ T cells requires the coordinate action of interleukin-12 and interferon-gamma and is inhibited by transforming growth factor-beta

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2805%2970059-5

7 January 2021

Evidence that CD4+, but not CD8+ T cells are responsible for murine interleukin‐2‐deficient colitis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2805%2970059-5

7 January 2021

T-cell costimulation via CD28-CD80/CD86 and CD40-CD40 ligand interactions

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2805%2970059-5

7 January 2021

Up-regulation of transforming growth factor alpha binding sites in experimental rabbit colitis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2805%2970059-5

7 January 2021

Traffic signals for lymphocyte recirculation and leukocyte emigration: the multistep paradigm

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2805%2970059-5

7 January 2021

Lack of effectiveness of the platelet-activating factor antagonist SR27417A in patients with active ulcerative colitis: a randomized controlled trial. The Platelet Activating Factor Antagonist Study Group in Ulcerative Colitis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2805%2970059-5

7 January 2021

Randomised controlled trial of CDP571 antibody to tumour necrosis factor-alpha in Crohn's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2805%2970059-5

7 January 2021

Dietary Supplementation with Fish Oil in Ulcerative Colitis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2805%2970059-5

7 January 2021

CD4 antibody treatment in patients with active Crohn's disease: a phase 1 dose finding study

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2805%2970059-5

7 January 2021

Basic fibroblast growth factor and PDGF in GI diseases

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2805%2970059-5

7 January 2021

A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2805%2970059-5

7 January 2021

The germfree state prevents development of gut and joint inflammatory disease in HLA-B27 transgenic rats

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2805%2970059-5

7 January 2021

Effect of nicotine on large bowel mucus thickness, eicosanoids and faecal proteinase in ferrets

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2805%2970059-5

7 January 2021

Transdermal nicotine as maintenance therapy for ulcerative colitis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2805%2970059-5

7 January 2021

Increased faecal mucin sulphatase activity in ulcerative colitis: a potential target for treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2805%2970059-5

7 January 2021

Rediscovering thalidomide: a review of its mechanism of action, side effects, and potential uses

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2805%2970059-5

7 January 2021

Long-term treatment of ulcerative colitis with ciprofloxacin: a prospective, double-blind, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2805%2970059-5

7 January 2021

Multiple doses of intravenous interleukin 10 in steroid-refractory Crohn's disease. Crohn's Disease Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2805%2970059-5

7 January 2021

Nicotine inhibits cytokine synthesis by mouse colonic mucosa

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2805%2970059-5

7 January 2021

Treatment of Crohn's disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2).

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2805%2970059-5

7 January 2021

Short‐chain fatty acid topical treatment in distal ulcerative colitis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2805%2970059-5

7 January 2021

Substance P promotes lymphocyte-endothelial cell adhesion preferentially via LFA-1/ICAM-1 interactions

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2805%2970059-5

7 January 2021

Treatment of ulcerative colitis with thalidomide

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2805%2970059-5

7 January 2021

Treatment of ulcerative colitis in the cottontop tamarin using antibody to tumour necrosis factor alpha

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2805%2970059-5

7 January 2021

Modification of in vivo and in vitro TNF-alpha, IL-1, and IL-6 secretion by circulating monocytes during hyperbaric oxygen treatment in patients with perianal Crohn's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2805%2970059-5

7 January 2021

Thalidomide in Crohn's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2805%2970059-5

7 January 2021

A placebo-controlled trial of ICAM-1 antisense oligonucleotide in the treatment of Crohn's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2805%2970059-5

7 January 2021

Immunomodulatory action of levofloxacin on cytokine production by human peripheral blood mononuclear cells

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2805%2970059-5

7 January 2021

Keratinocyte growth factor ameliorates mucosal injury in an experimental model of colitis in rats.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2805%2970059-5

7 January 2021

Pharmacokinetics of nicotine tartrate after single-dose liquid enema, oral, and intravenous administration

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2805%2970059-5

7 January 2021

Mechanism of action of hydroxychloroquine as an antirheumatic drug

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2805%2970059-5

7 January 2021

10.1016/S0889-8553(05)70059-5

Identifiers

DOI

1 reference

28 July 2017

1 reference